CASTRATION RESISTANT PROSTATE CANCER (CRPC)
Clinical trials for CASTRATION RESISTANT PROSTATE CANCER (CRPC) explained in plain language.
Never miss a new study
Get alerted when new CASTRATION RESISTANT PROSTATE CANCER (CRPC) trials appear
Sign up with your email to follow new studies for CASTRATION RESISTANT PROSTATE CANCER (CRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug IDE574 aims to shrink tumors in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called IDE574 in people with advanced solid tumors (like lung, prostate, or colorectal cancer) and a specific type of breast cancer (ER+, HER2-). The drug targets two enzymes that help cancer cells grow. The study will check if IDE574 is safe and can s…
Matched conditions: CASTRATION RESISTANT PROSTATE CANCER (CRPC)
Phase: PHASE1, PHASE2 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Radioactive antibody targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called 177LuBetaBart for people with advanced solid tumors that have stopped responding to standard therapies. The treatment combines a targeting antibody with a radioactive particle to deliver radiation directly to cancer cells. The s…
Matched conditions: CASTRATION RESISTANT PROSTATE CANCER (CRPC)
Phase: PHASE1, PHASE2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated May 11, 2026 20:39 UTC